Abstract
Objectives To describe the use and findings of cardiopulmonary imaging - chest X-ray (cX-ray), echocardiography (cEcho), chest CT (cCT), lung ultrasound (LUS)) and/or cardiac magnetic resonance imaging (cMRI) - in COVID-19-associated hospitalizations in Latin America (LATAM)
Background The SARS-Cov-2 is one of the largest and most active threats to healthcare in living memory. There is an information gap on imaging services resources (ISR) used and their findings during the pandemic in LATAM.
Methods This was a multicenter, prospective, observational study of COVID-19 inpatients conducted from March to December 2020 from 12 high-complexity centers in nine LATAM countries. Adults (> 18 yrs) with at least one imaging modality performed, followed from admission until discharge and/or in-hospital death, were included.
Results We studied 1435 hospitalized patients (64% males) with a median age of 58 years classified into three regions: 262 from Mexico (Mx), 428 from Central America and Caribbean (CAC), and 745 from South America (SAm). More frequent comorbidities were overweight/obesity (61%), hypertension (45%), and diabetes (27%). During hospitalization, 58% were admitted to ICU. The in-hospital mortality was 28% (95%CI 25-30) highest in Mx (37%).
The most frequent cardiopulmonary imaging performed were cCT (61%)-more frequent in Mx and SAm-, and cX-ray (46%) -significantly used in CAC-. The cEcho was carried out in 18%, similarly among regions, and LUS in 7%, more frequently in Mx. The cMRI was performed in only one patient in the cohort. Abnormal findings on the cX-ray were related to peripheral (63%) or basal infiltrates (52%), and in cCT with ground glass infiltrates (89%). Both were more commonly in Mx. In LUS, interstitial syndrome (56%) was the most related abnormal finding, predominantly in Mx and CAC.
Conclusions The use and findings of cardiopulmonary imaging in LATAM varied between regions and may have been influenced by clinical needs, the personnel protection measures and/or hospitalization location.
Condensed Abstract The SARS-Cov-2 is one of the largest and most active threats to healthcare in living memory. There is limited information on imaging services resources (ISR) used and their findings during the pandemic in LATAM.
To our knowledge, RIMAC aimed the first international, multicenter study at registering the use and findings of cardiopulmonary imaging modalities performed for the diagnosis, prognosis, and treatment of patients hospitalized for infection with SARS-CoV-2 in Latin America. We studied their demographic parameters, comorbidities, in-hospital events, laboratory results, and treatments focusing on their impact in clinical complications.
- Cardiopulmonary Images
- SARS-CoV-2
- COVID-19
- LATAM
- RIMAC
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Hospital Israelita Albert Einstein, Sao Paulo, Brazil; CEDIMAT, Santo Domingo, Republica Dominicana; Hospital General de Medellin, Medellin, Colombia; Clinica Davila, Santiago de Chile, Chile; Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de Mexico, Mexico; HNG Almenara Irigoyen, Lima, Peru; Hospital El Cruce, Provincia Buenos Aires, Argentina; Centro Medico Nacional 20 de Noviembre, Ciudad de Mexico, Mexico; Hospital general de Zona Numero 4, Monterrey, Mexico; Hospital Nossa Senhora das Gracas y Universidade Federal do Parana, Brazil; Complejo Hospitalario Dr Arnulfo Arias Madrid, Ciudad de Panama, Panama; and TECNISCAN Hospitalia, Ciudad de Guatemala, Guatemala gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
salvadorvspina{at}gmail.com
mluiz766{at}terra.com.br
cjherrera{at}cedimat.net
anagm{at}une.net.co
pamerojo{at}gmail.com
almasthelaarrioja{at}gmail.com
vazyur{at}yahoo.com.mx
betobaltodano97{at}gmail.com
grareyes{at}hotmail.com
rocioacevesmillan{at}yahoo.es
calderongonzalez{at}hotmail.com
a.camarozano{at}yahoo.com.br
osalocorp3{at}gmail.com
drmarcocabrera{at}gmail.com
maria.grande{at}hospitalitaliano.org.ar
lowensteinjorge{at}hotmail.com
rhvmd{at}hotmail.com
pamelapina24{at}gmail.com
iandres.jaime{at}uces.edu.co
alerivera.palma{at}gmail.com
bety1602{at}hotmail.com
medalidchacalcaje{at}hotmail.com
marielads1983{at}gmail.com
afonsotaniaregina1{at}gmail.com
tomas.miranda88{at}gmail.com
analalyre{at}gmail.com
drabeatrizdominguez{at}gmail.com
fcrosario70{at}gmail.com
sergioalday1{at}hotmail.com
angie_vale00{at}hotmail.com
danielaalvarez03{at}hotmail.com
patyroveri{at}hotmail.com
cixcamparij{at}prodigy.net.mx
enderotoniel{at}yahoo.es
dr.p_vargas{at}hotmail.com
max.fl94{at}gmail.com
rllopez99{at}hotmail.com
lucianameza{at}live.com.ar
samirasaady{at}gmail.com
ruru_mica{at}yahoo.com
stalinmartinezb{at}gmail.com
oscperorp{at}hotmail.com
tano369{at}yahoo.com.ar
mariaveronicaespinoza{at}yahoo.es
j.martebaez{at}yahoo.com
c_orisan{at}hotmail.com
marcosgranillof{at}yahoo.com.ar
loomba.rohit{at}gmail.com
saul.flores2{at}bcm.edu
drchemahdez{at}gmail.com
cardop{at}bcm.edu
The authors declare no conflicts of interest.
Fundings: RIMAC was designed and conducted by SISIAC (Society of Cardiovascular Images of the Inter-American Society of Cardiology). SISIAC is a non-profit academic-scientific entity that involves 23 countries throughout the Americas. It was founded in 2004 with the initial name of ECOSIAC.
This study is not sponsored by any public or private entity, nor will it have any remuneration or charge for the researchers who participate in it.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- BMI
- Body Mass Index
- CAC
- Central America and Caribbean region
- cCT
- chest computed tomography
- cEcho
- echocardiogram
- cMRI
- cardiac magnetic resonance imaging
- COPD
- Chronic obstructive pulmonary disease
- cX-ray
- chest R-ray
- DBT
- diabetes
- ECG
- electrocardiogram
- FaRV
- right ventricular fractional area
- FWSRV
- right ventricular free wall strain
- GLSLV
- left ventricular global longitudinal strain
- HBP
- high blood pressure
- ICU
- intensive care unit
- IRB
- institutional Review Board
- ISR
- imaging services resources
- LUS
- lung ultrasound
- LVEF
- left ventricular ejection fraction
- MV
- mechanical ventilation
- Mx
- Mexican region
- SAm
- South America region